ATE446752T1 - Hemmer der akt aktivität - Google Patents
Hemmer der akt aktivitätInfo
- Publication number
- ATE446752T1 ATE446752T1 AT04750420T AT04750420T ATE446752T1 AT E446752 T1 ATE446752 T1 AT E446752T1 AT 04750420 T AT04750420 T AT 04750420T AT 04750420 T AT04750420 T AT 04750420T AT E446752 T1 ATE446752 T1 AT E446752T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- activity inhibitor
- act activity
- directed
- act
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46512503P | 2003-04-24 | 2003-04-24 | |
| PCT/US2004/012265 WO2004096135A2 (en) | 2003-04-24 | 2004-04-20 | Inhibitors of akt activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446752T1 true ATE446752T1 (de) | 2009-11-15 |
Family
ID=33418188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750420T ATE446752T1 (de) | 2003-04-24 | 2004-04-20 | Hemmer der akt aktivität |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7414055B2 (de) |
| EP (1) | EP1631548B1 (de) |
| JP (1) | JP4679514B2 (de) |
| CN (1) | CN1809536A (de) |
| AT (1) | ATE446752T1 (de) |
| AU (1) | AU2004233835B2 (de) |
| CA (1) | CA2522435C (de) |
| DE (1) | DE602004023838D1 (de) |
| WO (1) | WO2004096135A2 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1622616B1 (de) * | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Hemmer der akt aktivität |
| ATE499364T1 (de) | 2004-04-09 | 2011-03-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
| WO2005100356A1 (en) | 2004-04-09 | 2005-10-27 | Merck & Co., Inc. | Inhibitors of akt activity |
| US7898642B2 (en) | 2004-04-14 | 2011-03-01 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| EP1781288A2 (de) * | 2004-08-19 | 2007-05-09 | Vertex Pharmaceuticals Incorporated | Modulatoren von muskarinischen rezeptoren |
| US7544677B2 (en) * | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| RU2007124373A (ru) * | 2004-11-29 | 2009-01-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецептеров |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| NZ563423A (en) * | 2005-06-10 | 2010-05-28 | Merck Sharp & Dohme | Inhibitors of AKT activity |
| MX2008001538A (es) | 2005-08-02 | 2008-04-04 | Lexicon Pharmaceuticals Inc | Aril piridinas y metodos para su uso. |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007087246A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
| RU2008137593A (ru) * | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецепторов |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| EP2120951A4 (de) * | 2006-12-06 | 2012-02-15 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| CA2700724A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US8207169B2 (en) * | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| US8536193B2 (en) * | 2008-06-03 | 2013-09-17 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递***在制备恶性肿瘤靶向治疗药物中的应用 |
| EP2361242B1 (de) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidaseinhibitoren und deren verwendung |
| WO2010084160A1 (en) * | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US8168652B2 (en) | 2009-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (de) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung |
| WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| MX352661B (es) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| RS57331B1 (sr) | 2010-07-29 | 2018-08-31 | Oryzon Genomics Sa | Inhibitori demetilaze za lsd1 zasnovani na arilciklopropilaminu i njihova medicinska upotreba |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2712315B1 (de) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysindemethylase-hemmer für myeloproliferative erkrankungen |
| CA2833935C (en) | 2011-05-04 | 2020-09-15 | Dhanapalan Nagarathnam | Novel compounds as modulators of protein kinases |
| EP2741741A2 (de) * | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysindemethylaseinhibitoren zur entzündungserkrankungen oder -zustände |
| CN104203914B (zh) | 2011-10-20 | 2017-07-11 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| GB201207722D0 (en) * | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| EP2870157B1 (de) | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selektive pi3k-delta-inhibitoren |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
| RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
| RU2016104643A (ru) | 2013-08-12 | 2017-09-19 | Токай Фармасьютикалз, Инк. | Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668A4 (de) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5-inhibitoren |
| AU2020408148A1 (en) | 2019-12-17 | 2022-06-16 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US690584A (en) * | 1901-04-22 | 1902-01-07 | Davied Hutton | Noria. |
| NZ230121A (en) | 1988-08-29 | 1993-08-26 | Squibb & Sons Inc | Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels |
| US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5703100A (en) | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| EP0807104A2 (de) | 1995-02-02 | 1997-11-19 | Smithkline Beecham Plc | Heterozyklische verbindungen mit 5ht2c rezeptor antagonismus |
| US5686470A (en) | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US20020127214A1 (en) * | 1995-11-16 | 2002-09-12 | Hemmings Brian Arthur | RAC-protein kinase as therapeutic agent or in diagnostics |
| CA2241080A1 (en) | 1995-12-20 | 1997-06-26 | Medical Research Council | Control of protein synthesis, and screening method for agents |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| IL152807A0 (en) | 2000-05-30 | 2003-06-24 | Peptor Ltd | Protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1355885A1 (de) * | 2001-01-02 | 2003-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Als cyclooxygenaseinhibitoren geeignete pyridinderivate |
| WO2002083140A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| JP2004527531A (ja) * | 2001-04-10 | 2004-09-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療する方法 |
| WO2002083138A1 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| US20040116433A1 (en) | 2002-04-08 | 2004-06-17 | Owens Andrew Pate | Inhibitors of akt activity |
| WO2002083675A2 (en) | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
| JP4342939B2 (ja) | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
| PT1482924E (pt) * | 2002-03-05 | 2008-08-27 | Axys Pharm Inc | Inibidores de proteases da cisteína catepsina |
| AU2003226250B2 (en) * | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| US20050130977A1 (en) * | 2002-04-08 | 2005-06-16 | Lindsley Craig W. | Inhibitors of akt activity |
| WO2003084473A2 (en) | 2002-04-08 | 2003-10-16 | Merck & Co., Inc. | Method of treating cancer |
| JP4394960B2 (ja) * | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性阻害薬 |
| WO2003086404A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| US7399764B2 (en) * | 2002-10-30 | 2008-07-15 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
-
2004
- 2004-04-20 AU AU2004233835A patent/AU2004233835B2/en not_active Ceased
- 2004-04-20 WO PCT/US2004/012265 patent/WO2004096135A2/en active Application Filing
- 2004-04-20 DE DE602004023838T patent/DE602004023838D1/de not_active Expired - Lifetime
- 2004-04-20 EP EP04750420A patent/EP1631548B1/de not_active Expired - Lifetime
- 2004-04-20 CA CA2522435A patent/CA2522435C/en not_active Expired - Fee Related
- 2004-04-20 US US10/554,187 patent/US7414055B2/en not_active Expired - Fee Related
- 2004-04-20 CN CNA2004800170365A patent/CN1809536A/zh active Pending
- 2004-04-20 JP JP2006513183A patent/JP4679514B2/ja not_active Expired - Fee Related
- 2004-04-20 AT AT04750420T patent/ATE446752T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004096135A3 (en) | 2005-03-24 |
| EP1631548B1 (de) | 2009-10-28 |
| US7414055B2 (en) | 2008-08-19 |
| WO2004096135A2 (en) | 2004-11-11 |
| CA2522435A1 (en) | 2004-11-11 |
| JP2006524257A (ja) | 2006-10-26 |
| CN1809536A (zh) | 2006-07-26 |
| JP4679514B2 (ja) | 2011-04-27 |
| CA2522435C (en) | 2011-04-12 |
| EP1631548A4 (de) | 2007-10-31 |
| EP1631548A2 (de) | 2006-03-08 |
| AU2004233835B2 (en) | 2010-02-25 |
| AU2004233835A1 (en) | 2004-11-11 |
| US20060270673A1 (en) | 2006-11-30 |
| DE602004023838D1 (de) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| ATE461179T1 (de) | Hemmer der akt aktivität | |
| ATE400274T1 (de) | Hemmstoffe der akt aktivität | |
| ATE503483T1 (de) | Hemmer der akt aktivität | |
| ATE499364T1 (de) | Hemmer der akt aktivität | |
| WO2003086279A3 (en) | Inhibitors of akt activity | |
| WO2004096130A3 (en) | Inhibitors of akt activity | |
| WO2006036395A3 (en) | Inhibitors of akt activity | |
| CA2480800A1 (en) | Inhibitors of akt activity | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| DK1648905T3 (da) | Inhibitorer for thienopyridin- og furopyridinkinase | |
| MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
| TNSN08020A1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| CY1111289T1 (el) | Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη | |
| TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |